Steven G. Deeks, MD

CFAR Mentees

CFAR Awards

Publications

  1. Lauring AS, Lee TH, Martin JN, Hunt PW, Deeks SG, Busch M. Lack of Evidence for mtDNA as a Biomarker of Innate Immune Activation in HIV Infection. PLoS One. 2012; 7(11):e50486. http://www.ncbi.nlm.nih.gov/pubmed/23209754
  2. Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R, Sinclair E, Palmer S, Martin JN, Busch MP, Deeks SG, Hsue PY. A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection. J Acquir Immune Defic Syndr. 2012 Nov 1; 61(3):317-25. http://www.ncbi.nlm.nih.gov/pubmed/22918156
  3. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults. J Acquir Immune Defic Syndr. 2012 Nov 1; 61(3):297-301. http://www.ncbi.nlm.nih.gov/pubmed/22878423
  4. Deeks SG, Gandhi RT, Chae CU, Lewandrowski KB. Case records of the Massachusetts General Hospital. Case 30-2012. A 54-year-old woman with HIV infection, dyspnea, and chest pain. N Engl J Med. 2012 Sep 27; 367(13):1246-54. http://www.ncbi.nlm.nih.gov/pubmed/23013077
  5. Lee GQ, Swenson LC, Poon AF, Martin JN, Hatano H, Deeks SG, Harrigan PR. Prolonged and Substantial Discordance in Prevalence of Raltegravir-Resistant HIV-1 in Plasma versus PBMC Samples Revealed by 454 "Deep" Sequencing. PLoS One. 2012; 7(9):e46181. http://www.ncbi.nlm.nih.gov/pubmed/23049972
  6. Tomescu C, Duh FM, Hoh R, Viviani A, Harvill K, Martin MP, Carrington M, Deeks SG, Montaner LJ. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS. 2012 Sep 24; 26(15):1869-78. http://www.ncbi.nlm.nih.gov/pubmed/22874514
  7. Selby VN, Scherzer R, Barnett CF, Macgregor JS, Morelli J, Donovan C, Deeks SG, Martin JN, Hsue PY. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. AIDS. 2012 Sep 24; 26(15):1967-9. http://www.ncbi.nlm.nih.gov/pubmed/22781217
  8. Geng EH, Hare CB, Kahn JO, Jain V, Van Nunnery T, Christopoulos K, Deeks SG, Gandhi M, Havlir DV. The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels among HIV-Infected Patients Entering Care with a CD4 Count Greater than 500/µl in a Public Health Setting. Clin Infect Dis. 2012 Sep 5. http://www.ncbi.nlm.nih.gov/pubmed/22955429
  9. Deeks SG. HIV infection, lymphoid fibrosis, and disease. Blood. 2012 Aug 30; 120(9):1753-4. http://www.ncbi.nlm.nih.gov/pubmed/22936732
  10. Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H. Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia. Antimicrob Agents Chemother. 2012 Nov; 56(11):5998-6000. http://www.ncbi.nlm.nih.gov/pubmed/22890763
  11. Ormsby CE, Sengupta D, Tandon R, Deeks SG, Martin JN, Jones RB, Ostrowski MA, Garrison KE, Vázquez-Pérez JA, Reyes-Terán G, Nixon DF. Human Endogenous Retrovirus Expression Is Inversely Associated with Chronic Immune Activation in HIV-1 Infection. PLoS One. 2012; 7(8):e41021. http://www.ncbi.nlm.nih.gov/pubmed/22879884
  12. Lim H, Kane L, Schwartz JB, Hesdorffer CS, Deeks SG, Greig N, Ferrucci L, Goetzl EJ. Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients. Clin Exp Immunol. 2012 Aug; 169(2):182-9. http://www.ncbi.nlm.nih.gov/pubmed/22774993
  13. Deeks SG. HIV: Shock and kill. Nature. 2012 Jul 26; 487(7408):439-40. http://www.ncbi.nlm.nih.gov/pubmed/22836995
  14. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012 Aug; 12(8):607-14. http://www.ncbi.nlm.nih.gov/pubmed/22814509
  15. Deeks SG, Barré-Sinoussi F. Public health: Towards a cure for HIV. Nature. 2012 Jul 19; 487(7407):293-4. http://www.ncbi.nlm.nih.gov/pubmed/22810677
  16. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, Deeks SG, Deren S, Effros RB, Gebo K, Goronzy JJ, Justice AC, Landay A, Levin J, Miotti PG, Munk RJ, Nass H, Rinaldo CR, Shlipak MG, Tracy R, Valcour V, Vance DE, Walston JD, Volberding P. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012 Jul 1; 60 Suppl 1:S1-18. http://www.ncbi.nlm.nih.gov/pubmed/22688010
  17. Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF. Influence of HAART on Alternative Reading Frame Immune Responses over the Course of HIV-1 Infection. PLoS One. 2012; 7(6):e39311. http://www.ncbi.nlm.nih.gov/pubmed/22768072
  18. McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet. 2012 Oct 1; 21(19):4334-47. http://www.ncbi.nlm.nih.gov/pubmed/22718199
  19. Deeks SG, Verdin E, McCune JM. Immunosenescence and HIV. Curr Opin Immunol. 2012 Aug; 24(4):501-6. http://www.ncbi.nlm.nih.gov/pubmed/22658763
  20. Hsue PY, Deeks SG, Hunt PW. Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. J Infect Dis. 2012 Jun; 205 Suppl 3:S375-82. http://www.ncbi.nlm.nih.gov/pubmed/22577211
  21. Ho JE, Scherzer R, Hecht FM, Maka K, Selby V, Martin JN, Ganz P, Deeks SG, Hsue PY. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS. 2012 Jun 1; 26(9):1115-20. http://www.ncbi.nlm.nih.gov/pubmed/22382147
  22. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012 May 2; 4(132):132ra53. http://www.ncbi.nlm.nih.gov/pubmed/22553251
  23. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M. HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation. Clin Infect Dis. 2012 Jul; 55(1):126-36. http://www.ncbi.nlm.nih.gov/pubmed/22534147
  24. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012 Apr 24; 26(7):867-75. http://www.ncbi.nlm.nih.gov/pubmed/22313955
  25. Sacre K, Hunt PW, Hsue PY, Maidji E, Martin JN, Deeks SG, Autran B, McCune JM. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS. 2012 Apr 24; 26(7):805-14. http://www.ncbi.nlm.nih.gov/pubmed/22313962
  26. Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, Maka K, Martin JN, Ganz P, Deeks SG. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. J Am Heart Assoc. 2012 Apr; 1(2). http://www.ncbi.nlm.nih.gov/pubmed/23130122
  27. Parrinello CM, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, Xue X, Hunt PW, Deeks SG, Hodis HN, Kaplan RC. Cytomegalovirus Immunoglobulin G Antibody Is Associated With Subclinical Carotid Artery Disease Among HIV-Infected Women. J Infect Dis. 2012 Jun; 205(12):1788-96. http://www.ncbi.nlm.nih.gov/pubmed/22492856
  28. Hsue PY, Scherzer R, Grunfeld C, Nordstrom SM, Schnell A, Kohl LP, Nitta E, Martin JN, Deeks SG, Weiss EJ. HIV Infection Is Associated With Decreased Thrombin Generation. Clin Infect Dis. 2012 Apr; 54(8):1196-203. http://www.ncbi.nlm.nih.gov/pubmed/22438347
  29. Tassiopoulos K, Landay A, Collier AC, Connick E, Deeks SG, Hunt P, Lewis DE, Wilson C, Bosch R. CD28-Negative CD4+ and CD8+ T Cells in Antiretroviral Therapy-Naive HIV-Infected Adults Enrolled in Adult Clinical Trials Group Studies. J Infect Dis. 2012 Jun; 205(11):1730-8. http://www.ncbi.nlm.nih.gov/pubmed/22448010
  30. Baum PD, Young JJ, Schmidt D, Zhang Q, Hoh R, Busch M, Martin J, Deeks S, McCune JM. Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. Blood. 2012 Apr 12; 119(15):3469-77. http://www.ncbi.nlm.nih.gov/pubmed/22371879
  31. Chen H, Hayashi G, Lai OY, Dilthey A, Kuebler PJ, Wong TV, Martin MP, Fernandez Vina MA, McVean G, Wabl M, Leslie KS, Maurer T, Martin JN, Deeks SG, Carrington M, Bowcock AM, Nixon DF, Liao W. Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. PLoS Genet. 2012 Feb; 8(2):e1002514. http://www.ncbi.nlm.nih.gov/pubmed/22577363
  32. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, Fiellin DA, Vanasse GJ, Butt AA, Rodriguez-Barradas MC, Gibert C, Oursler KA, Deeks SG, Bryant K. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis. 2012 Apr; 54(7):984-94. http://www.ncbi.nlm.nih.gov/pubmed/22337823
  33. Kiem HP, Jerome KR, Deeks SG, McCune JM. Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease. Cell Stem Cell. 2012 Feb 3; 10(2):137-47. http://www.ncbi.nlm.nih.gov/pubmed/22305563
  34. Gandhi RT, Deeks SG. Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough? Clin Infect Dis. 2012 Mar; 54(5):733-5. http://www.ncbi.nlm.nih.gov/pubmed/22238162
  35. Papasavvas E, Hsue P, Reynolds G, Pistilli M, Hancock A, Martin JN, Deeks SG, Montaner LJ. Increased CD34(+)/KDR(+) cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects. Antivir Ther. 2012; 17(3):557-63. http://www.ncbi.nlm.nih.gov/pubmed/22300770
  36. Deepe RN, Kistner-Griffin E, Martin JN, Deeks SG, Pandey JP. Epistatic interactions between Fc (GM) and Fc?R genes and the host control of human immunodeficiency virus replication. Hum Immunol. 2012 Mar; 73(3):263-6. http://www.ncbi.nlm.nih.gov/pubmed/22213007
  37. Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol. 2012 Mar 1; 109(5):742-7. http://www.ncbi.nlm.nih.gov/pubmed/22169125
  38. Eriksson EM, Milush JM, Ho EL, Batista MD, Holditch SJ, Keh CE, Norris PJ, Keating SM, Deeks SG, Hunt PW, Martin JN, Rosenberg MG, Hecht FM, Nixon DF. Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood. 2012 Jan 19; 119(3):745-55. http://www.ncbi.nlm.nih.gov/pubmed/22134167
  39. Seu L, Burt TD, Witte JS, Martin JN, Deeks SG, McCune JM. Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. Genes Immun. 2012 Apr; 13(3):258-67. http://www.ncbi.nlm.nih.gov/pubmed/22048453
  40. Sips M, Sciaranghella G, Diefenbach T, Dugast AS, Berger CT, Liu Q, Kwon D, Ghebremichael M, Estes JD, Carrington M, Martin JN, Deeks SG, Hunt PW, Alter G. Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol. 2012 Jan; 5(1):30-40. http://www.ncbi.nlm.nih.gov/pubmed/21993602
  41. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune Activation in the Pathogenesis of Treated Chronic HIV Disease: A Workshop Summary. AIDS Res Hum Retroviruses. 2012 May; 28(5):469-77. http://www.ncbi.nlm.nih.gov/pubmed/21854232
  42. Rajasuriar R, Booth DR, Gouillou M, Spelman T, James I, Solomon A, Chua K, Stewart G, Deeks S, Bangsberg DR, Muzoora C, Cameron PU, Hunt P, Martin J, Lewin SR. The role of SNPs in the a-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. Genes Immun. 2012 Jan; 13(1):83-93. http://www.ncbi.nlm.nih.gov/pubmed/21938017
  43. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, Montaner JS. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010 Dec; 55(4):460-5. http://www.ncbi.nlm.nih.gov/pubmed/20838225
  44. Lundgren JD, Baxter J, Deeks SG, Lane HC. Biomarkers in HIV disease. Curr Opin HIV AIDS. 2010 Nov; 5(6):459-62. http://www.ncbi.nlm.nih.gov/pubmed/20978387
  45. Hatano H, Delwart EL, Norris PJ, Lee TH, Neilands TB, Kelley CF, Hunt PW, Hoh R, Linnen JM, Martin JN, Busch MP, Deeks SG. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS. 2010 Oct 23; 24(16):2535-9. http://www.ncbi.nlm.nih.gov/pubmed/20651585
  46. Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, Klein MB, Gebo KA. Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010 Oct 23; 24(16):2469-79. http://www.ncbi.nlm.nih.gov/pubmed/20829678
  47. Ferre AL, Hunt PW, McConnell DH, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL. HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol. 2010 Nov; 84(21):11020-9. http://www.ncbi.nlm.nih.gov/pubmed/20719952
  48. Cummins NW, Jiang W, McGinty J, Bren GD, Bosch RJ, Landay A, Deeks SG, Martin JN, Douek D, Lederman MM, Brenchley J, Badley AD. Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis. 2010 Aug 15; 202(3):386-91. http://www.ncbi.nlm.nih.gov/pubmed/20565257
  49. Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol. 2010 Oct; 84(20):10863-76. http://www.ncbi.nlm.nih.gov/pubmed/20702642
  50. Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nat Biotechnol. 2010 Aug; 28(8):807-10. http://www.ncbi.nlm.nih.gov/pubmed/20697404
  51. Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Aug; 54(4):389-93. http://www.ncbi.nlm.nih.gov/pubmed/20300008
  52. Ho JE, Deeks SG, Hecht FM, Xie Y, Schnell A, Martin JN, Ganz P, Hsue PY. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS. 2010 Jul 31; 24(12):1897-905. http://www.ncbi.nlm.nih.gov/pubmed/20543654
  53. Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J Virol. 2010 Oct; 84(19):10354-65. http://www.ncbi.nlm.nih.gov/pubmed/20668079
  54. Saag M, Deeks SG. How do HIV elite controllers do what they do? Clin Infect Dis. 2010 Jul 15; 51(2):239-41. http://www.ncbi.nlm.nih.gov/pubmed/20550453
  55. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010 Jul 3; 376(9734):49-62. http://www.ncbi.nlm.nih.gov/pubmed/20609987
  56. Geng EH, Glidden DV, Emenyonu N, Musinguzi N, Bwana MB, Neilands TB, Muyindike W, Yiannoutsos CT, Deeks SG, Bangsberg DR, Martin JN. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health. 2010 Jun; 15 Suppl 1:63-9. http://www.ncbi.nlm.nih.gov/pubmed/20586962
  57. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010 Jun 1; 50(11):1512-20. http://www.ncbi.nlm.nih.gov/pubmed/20415573
  58. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010 May 19; 2(32):32ra36. http://www.ncbi.nlm.nih.gov/pubmed/20484731
  59. Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, Martin JN, Krone MR, Deeks SG, Norris PJ. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS. 2010 May 15; 24(8):1095-105. http://www.ncbi.nlm.nih.gov/pubmed/20400885
  60. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, Deeks SG, Pereyra F, Carrington M, Walker BD, Chakraborty AK. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature. 2010 May 20; 465(7296):350-4. http://www.ncbi.nlm.nih.gov/pubmed/20445539
  61. Jain V, Deeks SG. When to start antiretroviral therapy. Curr HIV/AIDS Rep. 2010 May; 7(2):60-8. http://www.ncbi.nlm.nih.gov/pubmed/20425559
  62. Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, Deeks SG. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS. 2010 Apr 24; 24(7):941-5. http://www.ncbi.nlm.nih.gov/pubmed/20168202
  63. Probasco JC, Deeks SG, Lee E, Hoh R, Hunt PW, Liegler T, Price RW, Spudich SS. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. AIDS. 2010 Apr 24; 24(7):1001-5. http://www.ncbi.nlm.nih.gov/pubmed/20299968
  64. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, Glidden DV, Deeks SG, Martin JN. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010 Mar; 53(3):405-11. http://www.ncbi.nlm.nih.gov/pubmed/19745753
  65. Loke P, Favre D, Hunt PW, Leung JM, Kanwar B, Martin JN, Deeks SG, McCune JM. Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood. 2010 Apr 15; 115(15):e20-32. http://www.ncbi.nlm.nih.gov/pubmed/20160163
  66. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, Hsue P, McCune JM, Deeks SG. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010; 5(1):e8886. http://www.ncbi.nlm.nih.gov/pubmed/20126452
  67. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010 Feb 9; 121(5):651-8. http://www.ncbi.nlm.nih.gov/pubmed/20100969
  68. Bangsberg DR, Deeks SG. Spending more to save more: interventions to promote adherence. Ann Intern Med. 2010 Jan 5; 152(1):54-6; W-13. http://www.ncbi.nlm.nih.gov/pubmed/20048272
  69. Thomas R, Apps R, Qi Y, Gao X, Male V, O'hUigin C, O'Connor G, Ge D, Fellay J, Martin JN, Margolick J, Goedert JJ, Buchbinder S, Kirk GD, Martin MP, Telenti A, Deeks SG, Walker BD, Goldstein D, McVicar DW, Moffett A, Carrington M. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet. 2009 Dec; 41(12):1290-4. http://www.ncbi.nlm.nih.gov/pubmed/19935663
  70. Hsue PY, Hunt PW, Ho JE, Farah HH, Schnell A, Hoh R, Martin JN, Deeks SG, Bolger AF. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail. 2010 Jan; 3(1):132-9. http://www.ncbi.nlm.nih.gov/pubmed/19933410
  71. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15; 49(10):1582-90. http://www.ncbi.nlm.nih.gov/pubmed/19845473
  72. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS. 2009 Oct 23; 23(16):2143-9. http://www.ncbi.nlm.nih.gov/pubmed/19684507
  73. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009; 4(9):e7196. http://www.ncbi.nlm.nih.gov/pubmed/19787058
  74. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, Xie Y, Martin JN, Ganz P, Deeks SG. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009 Sep 24; 23(15):2021-7. http://www.ncbi.nlm.nih.gov/pubmed/19542863
  75. Snyder-Cappione JE, Loo CP, Carvalho KI, Kuylenstierna C, Deeks SG, Hecht FM, Rosenberg MG, Sandberg JK, Kallas EG, Nixon DF. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS. 2009 Sep 24; 23(15):1965-70. http://www.ncbi.nlm.nih.gov/pubmed/19590406
  76. Gress RE, Deeks SG. Reduced thymus activity and infection prematurely age the immune system. J Clin Invest. 2009 Oct; 119(10):2884-7. http://www.ncbi.nlm.nih.gov/pubmed/19770512
  77. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009 Sep-Oct; 17(4):118-23. http://www.ncbi.nlm.nih.gov/pubmed/19890183
  78. Jha AR, Pillai SK, York VA, Sharp ER, Storm EC, Wachter DJ, Martin JN, Deeks SG, Rosenberg MG, Nixon DF, Garrison KE. Cross-sectional dating of novel haplotypes of HERV-K 113 and HERV-K 115 indicate these proviruses originated in Africa before Homo sapiens. Mol Biol Evol. 2009 Nov; 26(11):2617-26. http://www.ncbi.nlm.nih.gov/pubmed/19666991
  79. Huang W, Toma J, Stawiski E, Fransen S, Wrin T, Parkin N, Whitcomb JM, Coakley E, Hecht FM, Deeks SG, Gandhi RT, Eshleman SH, Petropoulos CJ. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses. 2009 Aug; 25(8):795-802. http://www.ncbi.nlm.nih.gov/pubmed/19678765
  80. Garrison KE, Champiat S, York VA, Agrawal AT, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF. Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses. Clin Vaccine Immunol. 2009 Sep; 16(9):1369-71. http://www.ncbi.nlm.nih.gov/pubmed/19571107
  81. Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N, Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, Lazzarin A, McMichael AJ, Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M. A step ahead on the HIV collaboratory. Science. 2009 Jun 5; 324(5932):1264-5. http://www.ncbi.nlm.nih.gov/pubmed/19498149
  82. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009 Jun 1; 23(9):1059-67. http://www.ncbi.nlm.nih.gov/pubmed/19390417
  83. Jacobson MA, Ditmer DP, Sinclair E, Martin JN, Deeks SG, Hunt P, Mocarski ES, Shiboski C. Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients. PLoS One. 2009; 4(4):e5277. http://www.ncbi.nlm.nih.gov/pubmed/19381272
  84. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI, Deeks SG, Douek DC, Brenchley JM. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009 Apr 15; 199(8):1177-85. http://www.ncbi.nlm.nih.gov/pubmed/19265479
  85. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26. http://www.ncbi.nlm.nih.gov/pubmed/19339714
  86. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009 Mar 15; 48(6):787-94. http://www.ncbi.nlm.nih.gov/pubmed/19193107
  87. Tenorio AR, Jiang H, Zheng Y, Bastow B, Kuritzkes DR, Bartlett JA, Deeks SG, Landay AL, Riddler SA. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9. http://www.ncbi.nlm.nih.gov/pubmed/19239354
  88. Geng EH, Deeks SG. CD4+ T cell recovery with antiretroviral therapy: more than the sum of the parts. Clin Infect Dis. 2009 Feb 1; 48(3):362-4. http://www.ncbi.nlm.nih.gov/pubmed/19123869
  89. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009; 338:a3172. http://www.ncbi.nlm.nih.gov/pubmed/19171560
  90. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009 Mar 13; 284(11):6782-9. http://www.ncbi.nlm.nih.gov/pubmed/19136668
  91. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood. 2009 Apr 23; 113(17):3978-89. http://www.ncbi.nlm.nih.gov/pubmed/19109229
  92. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol. 2009 Feb; 83(4):2038-43. http://www.ncbi.nlm.nih.gov/pubmed/19019971
  93. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009 Jan; 83(1):329-35. http://www.ncbi.nlm.nih.gov/pubmed/18945778
  94. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008 Oct 18; 22(16):2097-106. http://www.ncbi.nlm.nih.gov/pubmed/18832873
  95. Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin JN, Deeks SG, Kuritzkes DR. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J Acquir Immune Defic Syndr. 2008 Aug 15; 48(5):572-6. http://www.ncbi.nlm.nih.gov/pubmed/18645515
  96. Probasco JC, Spudich SS, Critchfield J, Lee E, Lollo N, Deeks SG, Price RW. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology. 2008 Aug 12; 71(7):521-4. http://www.ncbi.nlm.nih.gov/pubmed/18695163
  97. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, Bangsberg DR. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008; 3(7):e2783. http://www.ncbi.nlm.nih.gov/pubmed/18665246
  98. Deeks SG. Transmitted minority drug-resistant HIV variants: a new epidemic? PLoS Med. 2008 Jul 29; 5(7):e164. http://www.ncbi.nlm.nih.gov/pubmed/18666826
  99. Schweneker M, Favre D, Martin JN, Deeks SG, McCune JM. HIV-induced changes in T cell signaling pathways. J Immunol. 2008 May 15; 180(10):6490-500. http://www.ncbi.nlm.nih.gov/pubmed/18453567
  100. Hsue PY, Deeks SG, Farah HH, Palav S, Ahmed SY, Schnell A, Ellman AB, Huang L, Dollard SC, Martin JN. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS. 2008 Apr 23; 22(7):825-33. http://www.ncbi.nlm.nih.gov/pubmed/18427200
  101. Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):544-52. http://www.ncbi.nlm.nih.gov/pubmed/18362693
  102. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008 Apr; 14(4):413-20. http://www.ncbi.nlm.nih.gov/pubmed/18376407
  103. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol. 2008 Jun; 82(11):5398-407. http://www.ncbi.nlm.nih.gov/pubmed/18353945
  104. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008 Jan 1; 197(1):126-33. http://www.ncbi.nlm.nih.gov/pubmed/18171295
  105. Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SG. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther. 2008; 13(3):369-74. http://www.ncbi.nlm.nih.gov/pubmed/18572749
  106. Barker E, Martinson J, Brooks C, Landay A, Deeks S. Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS. 2007 Nov 12; 21(17):2363-5. http://www.ncbi.nlm.nih.gov/pubmed/18090295
  107. Petersen ML, Deeks SG, van der Laan MJ. Individualized treatment rules: generating candidate clinical trials. Stat Med. 2007 Nov 10; 26(25):4578-601. http://www.ncbi.nlm.nih.gov/pubmed/17450501
  108. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, Miura T, Hecht FM, Mamtani M, Pereyra F, Marconi V, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J, O'Connell RJ, Lloyd A, Martin J, Ahuja SS, Agan BK, Walker BD, Deeks SG, Ahuja SK. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol. 2007 Dec; 8(12):1324-36. http://www.ncbi.nlm.nih.gov/pubmed/17952079
  109. Petersen ML, Deeks SG, Martin JN, van der Laan MJ. History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol. 2007 Nov 1; 166(9):985-93. http://www.ncbi.nlm.nih.gov/pubmed/17875580
  110. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007 Sep; 27(3):406-16. http://www.ncbi.nlm.nih.gov/pubmed/17892849
  111. Deeks SG. Protease inhibitors as immunomodulatory drugs for HIV infection. Clin Pharmacol Ther. 2007 Sep; 82(3):248-50. http://www.ncbi.nlm.nih.gov/pubmed/17700590
  112. Owen RE, Sinclair E, Emu B, Heitman JW, Hirschkorn DF, Epling CL, Tan QX, Custer B, Harris JM, Jacobson MA, McCune JM, Martin JN, Hecht FM, Deeks SG, Norris PJ. Loss of T cell responses following long-term cryopreservation. J Immunol Methods. 2007 Sep 30; 326(1-2):93-115. http://www.ncbi.nlm.nih.gov/pubmed/17707394
  113. Karlsson AC, Chapman JM, Heiken BD, Hoh R, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF. Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol. 2007 Oct; 81(20):11543-8. http://www.ncbi.nlm.nih.gov/pubmed/17670829
  114. Lederman MM, Miller V, Weller I, Deeks SG. A new approach for 'deep salvage' trials in advanced HIV infection. AIDS. 2007 Jul 31; 21(12):1503-6. http://www.ncbi.nlm.nih.gov/pubmed/17630543
  115. Hatano H, Deeks SG. Drug resistant HIV. BMJ. 2007 Jun 2; 334(7604):1124-5. http://www.ncbi.nlm.nih.gov/pubmed/17540912
  116. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD, Telenti A, Connors M, O'Brien SJ, Walker BD, Parham P, Deeks SG, McVicar DW, Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007 Jun; 39(6):733-40. http://www.ncbi.nlm.nih.gov/pubmed/17496894
  117. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May; 4(2):65-72. http://www.ncbi.nlm.nih.gov/pubmed/17547827
  118. Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol. 2007 Apr; 81(7):3240-50. http://www.ncbi.nlm.nih.gov/pubmed/17251281
  119. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007 Apr 1; 175(7):737-42. http://www.ncbi.nlm.nih.gov/pubmed/17218620
  120. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. 2007 Apr; 36(2):294-301. http://www.ncbi.nlm.nih.gov/pubmed/17213214
  121. Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP, Landay A, Bastow B, Haas DW, Tashima KT, Jain MK, Deeks SG, Bartlett JA. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41. http://www.ncbi.nlm.nih.gov/pubmed/17668562
  122. Deeks SG, Martin JN. Partial treatment interruptions. Curr Opin HIV AIDS. 2007 Jan; 2(1):46-55. http://www.ncbi.nlm.nih.gov/pubmed/19372865
  123. Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis. 2007 Feb 1; 195(3):387-91. http://www.ncbi.nlm.nih.gov/pubmed/17205477
  124. Kitchen CM, Lu J, Suchard MA, Hoh R, Martin JN, Kuritzkes DR, Deeks SG. Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1260-6. http://www.ncbi.nlm.nih.gov/pubmed/17209769
  125. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, Hoh R, Martin JN, McCune JM, Waters DD, Deeks SG. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006 Nov 28; 20(18):2275-83. http://www.ncbi.nlm.nih.gov/pubmed/17117013
  126. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec; 12(12):1365-71. http://www.ncbi.nlm.nih.gov/pubmed/17115046
  127. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006 Dec 15; 194(12):1686-96. http://www.ncbi.nlm.nih.gov/pubmed/17109340
  128. Hunt PW, Deeks SG. Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J Infect Dis. 2006 Dec 15; 194(12):1632-4. http://www.ncbi.nlm.nih.gov/pubmed/17109333
  129. Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA. A plea for justice for jailed medical workers. Science. 2006 Nov 10; 314(5801):924-5. http://www.ncbi.nlm.nih.gov/pubmed/17062652
  130. Hatano H, Hunt P, Weidler J, Coakley E, Hoh R, Liegler T, Martin JN, Deeks SG. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis. 2006 Nov 15; 43(10):1329-36. http://www.ncbi.nlm.nih.gov/pubmed/17051502
  131. Rodríguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, Boswell SL, Mathews WC, Bangsberg DR, Martin J, Whalen CC, Sieg S, Yadavalli S, Deeks SG, Lederman MM. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006 Sep 27; 296(12):1498-506. http://www.ncbi.nlm.nih.gov/pubmed/17003398
  132. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, Kuritzkes DR. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr. 2006 Sep; 43(1):60-4. http://www.ncbi.nlm.nih.gov/pubmed/16885776
  133. Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J Clin Microbiol. 2006 Sep; 44(9):3384-7. http://www.ncbi.nlm.nih.gov/pubmed/16954280
  134. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris H, Hoh R, Leigler T, Martin JN, Deeks SG. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006 Oct 1; 194(7):926-30. http://www.ncbi.nlm.nih.gov/pubmed/16960780
  135. Nomura LE, Emu B, Hoh R, Haaland P, Deeks SG, Martin JN, McCune JM, Nixon DF, Maecker HT. IL-2 production correlates with effector cell differentiation in HIV-specific CD8+ T cells. AIDS Res Ther. 2006; 3:18. http://www.ncbi.nlm.nih.gov/pubmed/16859558
  136. Deeks SG. Antiretroviral treatment of HIV infected adults. BMJ. 2006 Jun 24; 332(7556):1489. http://www.ncbi.nlm.nih.gov/pubmed/16793811
  137. Deeks SG. The risk of treatment versus the risk of HIV replication. Lancet. 2006 Jun 17; 367(9527):1955-6. http://www.ncbi.nlm.nih.gov/pubmed/16782465
  138. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol. 2006 Jun; 80(12):6155-64. http://www.ncbi.nlm.nih.gov/pubmed/16731954
  139. Wilson-Clark SD, Squires S, Deeks S. Bacterial meningitis among cochlear implant recipients--Canada, 2002. MMWR Morb Mortal Wkly Rep. 2006 Apr 28; 55 Suppl 1:20-4. http://www.ncbi.nlm.nih.gov/pubmed/16645578
  140. Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, Bates M, Tsao G, Lampiris H, Hoh R, Martin JN. The independent effect of drug resistance on T cell activation in HIV infection. AIDS. 2006 Mar 21; 20(5):691-9. http://www.ncbi.nlm.nih.gov/pubmed/16514299
  141. Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. Lancet. 2006 Mar 4; 367(9512):711-3. http://www.ncbi.nlm.nih.gov/pubmed/16517257
  142. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006 Jan 9; 20(2):223-31. http://www.ncbi.nlm.nih.gov/pubmed/16511415
  143. Jordan KA, Furlan SN, Gonzalez VD, Karlsson AC, Quigley MF, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK. CD8 T cell effector maturation in HIV-1-infected children. Virology. 2006 Mar 30; 347(1):117-26. http://www.ncbi.nlm.nih.gov/pubmed/16406047
  144. Beatty G, Hunt P, Smith A, Hoh R, Huang W, Martin J, Deeks SG. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. Antivir Ther. 2006; 11(3):315-9. http://www.ncbi.nlm.nih.gov/pubmed/16759047
  145. Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant RM, Martin JN. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. J Acquir Immune Defic Syndr. 2005 Dec 1; 40(4):463-71. http://www.ncbi.nlm.nih.gov/pubmed/16280703
  146. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis. 2005; 5:98. http://www.ncbi.nlm.nih.gov/pubmed/16266436
  147. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol. 2005 Nov; 79(22):14169-78. http://www.ncbi.nlm.nih.gov/pubmed/16254352
  148. Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, Wiznia AA, Nixon DF, Rosenberg MG. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS. 2005 Oct 14; 19(15):1575-85. http://www.ncbi.nlm.nih.gov/pubmed/16184026
  149. Lo JC, Kazemi MR, Hsue PY, Martin JN, Deeks SG, Schambelan M, Mulligan K. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis. 2005 Nov 1; 41(9):1335-40. http://www.ncbi.nlm.nih.gov/pubmed/16206112
  150. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 1; 192(9):1537-44. http://www.ncbi.nlm.nih.gov/pubmed/16206068
  151. Gisslén M, Rosengren L, Hagberg L, Deeks SG, Price RW. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther. 2005 Aug 18; 2:6. http://www.ncbi.nlm.nih.gov/pubmed/16109178
  152. Cohan D, Feakins C, Wara D, Petru A, McNicholl I, Schillinger D, Lu J, Kuritzkes D, Deeks SG. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS. 2005 Jun 10; 19(9):989-90. http://www.ncbi.nlm.nih.gov/pubmed/15905684
  153. Nixon DF, Deeks SG, Shacklett BL, Karlsson AC. Multidrug-resistant, dual-tropic HIV-1 and rapid progression. Lancet. 2005 Jun 4-10; 365(9475):1924-5. http://www.ncbi.nlm.nih.gov/pubmed/15936414
  154. McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H. Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. Vaccine. 2005 Jul 14; 23(32):4128-35. http://www.ncbi.nlm.nih.gov/pubmed/15964481
  155. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004 Sep 24; 18(14):1965-6. http://www.ncbi.nlm.nih.gov/pubmed/15353986
  156. Critchfield JM, Deeks SG. Treating the latent reservoir of HIV. AIDS Read. 2004 Sep; 14(9):485-6. http://www.ncbi.nlm.nih.gov/pubmed/15457601
  157. Aandahl EM, Quigley MF, Moretto WJ, Moll M, Gonzalez VD, Sönnerborg A, Lindbäck S, Hecht FM, Deeks SG, Rosenberg MG, Nixon DF, Sandberg JK. Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. Blood. 2004 Dec 1; 104(12):3672-8. http://www.ncbi.nlm.nih.gov/pubmed/15308569
  158. Elrefaei M, McElroy MD, Preas CP, Hoh R, Deeks S, Martin J, Cao H. Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol. 2004 Aug 1; 173(3):2184-9. http://www.ncbi.nlm.nih.gov/pubmed/15265956
  159. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, Guzman D, Clark R, Moss A. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis. 2004 Jul 1; 190(1):162-5. http://www.ncbi.nlm.nih.gov/pubmed/15195256
  160. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004 Apr 30; 18(7):981-9. http://www.ncbi.nlm.nih.gov/pubmed/15096800
  161. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004 Aug 15; 104(4):942-7. http://www.ncbi.nlm.nih.gov/pubmed/15117761
  162. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004 May; 53(5):696-9. http://www.ncbi.nlm.nih.gov/pubmed/15044425
  163. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004 Apr 6; 109(13):1603-8. http://www.ncbi.nlm.nih.gov/pubmed/15023877
  164. Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest. 2004 Mar; 113(6):808-10. http://www.ncbi.nlm.nih.gov/pubmed/15067312
  165. Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, Hagos E, Wrin T, Petropoulos CJ, Bredt B, McCune JM. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis. 2004 Jan 15; 189(2):312-21. http://www.ncbi.nlm.nih.gov/pubmed/14722897
  166. Price RW, Deeks SG. Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. J Neurovirol. 2004; 10 Suppl 1:44-51. http://www.ncbi.nlm.nih.gov/pubmed/14982739
  167. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003 Dec 13; 362(9400):2002-11. http://www.ncbi.nlm.nih.gov/pubmed/14683662
  168. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, Varma A, Deeks SG, McCune JM, Nixon DF, Sinclair E. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods. 2003 Dec; 283(1-2):141-53. http://www.ncbi.nlm.nih.gov/pubmed/14659906
  169. Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, DeGruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003 Oct 1; 188(7):1001-8. http://www.ncbi.nlm.nih.gov/pubmed/14513420
  170. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003 Sep 5; 17(13):1907-15. http://www.ncbi.nlm.nih.gov/pubmed/12960823
  171. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003 Sep 5; 17(13):1925-32. http://www.ncbi.nlm.nih.gov/pubmed/12960825
  172. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003 Aug 19; 139(4):258-66. http://www.ncbi.nlm.nih.gov/pubmed/12965981
  173. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. http://www.ncbi.nlm.nih.gov/pubmed/12767994
  174. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003 May 15; 187(10):1534-43. http://www.ncbi.nlm.nih.gov/pubmed/12721933
  175. Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J. Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. AIDS. 2003 Apr 11; 17(6):917-9. http://www.ncbi.nlm.nih.gov/pubmed/12660541
  176. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003 Feb 14; 17(3):361-70. http://www.ncbi.nlm.nih.gov/pubmed/12556690
  177. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS. 2003 Jan 3; 17(1):53-63. http://www.ncbi.nlm.nih.gov/pubmed/12478069
  178. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002 Nov; 76(21):11104-12. http://www.ncbi.nlm.nih.gov/pubmed/12368352
  179. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002 Oct 18; 16(15):F41-7. http://www.ncbi.nlm.nih.gov/pubmed/12370521
  180. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med. 2002 Oct; 17(10):812-3. http://www.ncbi.nlm.nih.gov/pubmed/12390559
  181. Tebas P, Henry K, Mondy K, Deeks S, Valdez H, Cohen C, Powderly WG. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis. 2002 Sep 15; 186(6):851-4. http://www.ncbi.nlm.nih.gov/pubmed/12198623
  182. Castelli JC, Deeks SG, Shiboski S, Levy JA. Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals. Blood. 2002 Jun 1; 99(11):4225-7. http://www.ncbi.nlm.nih.gov/pubmed/12010831
  183. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. 2002 Jun; 5(6):788-97. http://www.ncbi.nlm.nih.gov/pubmed/12027564
  184. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002 Mar 1; 185(5):599-607. http://www.ncbi.nlm.nih.gov/pubmed/11865416
  185. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002 Jan 25; 16(2):201-7. http://www.ncbi.nlm.nih.gov/pubmed/11807304
  186. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002 Feb 1; 185(3):315-23. http://www.ncbi.nlm.nih.gov/pubmed/11807713
  187. Deeks SG, Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS. 2002; 16 Suppl 4:S157-69. http://www.ncbi.nlm.nih.gov/pubmed/12699013
  188. Deeks SG, Barditch-Crovo P, Collier A, Smith A, Miller M, McGowan I, Coakley DF. Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2001 Dec 1; 28(4):336-9. http://www.ncbi.nlm.nih.gov/pubmed/11707669
  189. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001 Oct; 45(10):2733-9. http://www.ncbi.nlm.nih.gov/pubmed/11557462
  190. Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, Napolitano LA, Douek DC, Mbisa G, Deeks S, Harris JM, Barbour JD, Gross BH, Francis IR, Halvorsen R, Asaad R, Lederman MM. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001 Sep 28; 15(14):1749-56. http://www.ncbi.nlm.nih.gov/pubmed/11579235
  191. Deeks SG. Durable HIV treatment benefit despite low-level viremia: reassessing definitions of success or failure. JAMA. 2001 Jul 11; 286(2):224-6. http://www.ncbi.nlm.nih.gov/pubmed/11448286
  192. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS. 2001 Jul 6; 15(10):1251-9. http://www.ncbi.nlm.nih.gov/pubmed/11426069
  193. Sabin CA, Olmscheid B, Moyle G, Carr A, Boyle B, Cohen C, Cooper D, Deeks S, Gulick T, Saag M. Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois. HIV Clin Trials. 2001 Jul-Aug; 2(4):366-86. http://www.ncbi.nlm.nih.gov/pubmed/11590541
  194. Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, Grant RM, Clavel F, McCune JM. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001 Jun; 7(6):712-8. http://www.ncbi.nlm.nih.gov/pubmed/11385509
  195. Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant RM, Goldsmith MA. Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):517-23. http://www.ncbi.nlm.nih.gov/pubmed/11350665
  196. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001 Mar 1; 26 Suppl 1:S25-33. http://www.ncbi.nlm.nih.gov/pubmed/11264999
  197. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001 Feb 15; 344(7):472-80. http://www.ncbi.nlm.nih.gov/pubmed/11172188
  198. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis. 2001 Feb; 14(1):23-8. http://www.ncbi.nlm.nih.gov/pubmed/11979111
  199. Liegler TJ, Hayden MS, Lee KH, Hoh R, Deeks SG, Granta RM. Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes. AIDS. 2001 Jan 26; 15(2):179-84. http://www.ncbi.nlm.nih.gov/pubmed/11216925
  200. Deeks SG, Martin JN. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. AIDS. 2001 Jan 5; 15(1):117-9. http://www.ncbi.nlm.nih.gov/pubmed/11192853
  201. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, Herndier BG, Andersson J, McCune JM. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001 Jan; 7(1):73-9. http://www.ncbi.nlm.nih.gov/pubmed/11135619
  202. Parkin NT, Deeks SG, Wrin MT, Yap J, Grant RM, Lee KH, Heeren D, Hellmanna NS, Petropoulos CJ. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS. 2000 Dec 22; 14(18):2877-87. http://www.ncbi.nlm.nih.gov/pubmed/11153669
  203. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000 Aug 1; 96(3):785-93. http://www.ncbi.nlm.nih.gov/pubmed/10910888
  204. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000 Jun; 30 Suppl 2:S177-84. http://www.ncbi.nlm.nih.gov/pubmed/10860903
  205. McCune JM, Hanley MB, Cesar D, Halvorsen R, Hoh R, Schmidt D, Wieder E, Deeks S, Siler S, Neese R, Hellerstein M. Factors influencing T-cell turnover in HIV-1-seropositive patients. J Clin Invest. 2000 Mar; 105(5):R1-8. http://www.ncbi.nlm.nih.gov/pubmed/10712441
  206. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000 Mar; 181(3):946-53. http://www.ncbi.nlm.nih.gov/pubmed/10720517
  207. Huang SS, Barbour JD, Deeks SG, Huang JS, Grant RM, Ng VL, McCune JM. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000 Mar; 30(3):504-10. http://www.ncbi.nlm.nih.gov/pubmed/10722435
  208. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ, Coakley D. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999 Dec 22-29; 282(24):2305-12. http://www.ncbi.nlm.nih.gov/pubmed/10612317
  209. Buxton J, Fyfe M, King A, Deeks S, Dore K, Ahmed R, Khakhria R, Paccagnella A, Hockin J. Salmonella typhimurium definitive type 104 isolates in British Columbia, 1997-1998. Can Commun Dis Rep. 1999 Aug 1; 25(15):129-33. http://www.ncbi.nlm.nih.gov/pubmed/10466255
  210. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999 Jun 18; 13(9):1051-61. http://www.ncbi.nlm.nih.gov/pubmed/10397535
  211. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999 Jun; 179(6):1375-81. http://www.ncbi.nlm.nih.gov/pubmed/10228057
  212. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999 Apr 16; 13(6):F35-43. http://www.ncbi.nlm.nih.gov/pubmed/10397555
  213. Deeks S, De Serres G, Boulianne N, Duval B, Rochette L, Déry P, Halperin S. Failure of physicians to consider the diagnosis of pertussis in children. Clin Infect Dis. 1999 Apr; 28(4):840-6. http://www.ncbi.nlm.nih.gov/pubmed/10825048
  214. Deeks SG. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. Adv Exp Med Biol. 1999; 458:175-82. http://www.ncbi.nlm.nih.gov/pubmed/10549390
  215. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999 Jan; 5(1):83-9. http://www.ncbi.nlm.nih.gov/pubmed/9883844
  216. Deeks SG, Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther. 1999; 4 Suppl 3:7-11. http://www.ncbi.nlm.nih.gov/pubmed/16021865
  217. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998 Sep; 42(9):2380-4. http://www.ncbi.nlm.nih.gov/pubmed/9736567
  218. Deeks SG, Sax PE. Should we argue with success? AIDS Clin Care. 1998 Sep; 10(9):68, 72. http://www.ncbi.nlm.nih.gov/pubmed/11365809
  219. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS. 1998 Jul 9; 12(10):F97-102. http://www.ncbi.nlm.nih.gov/pubmed/9677159
  220. Volberding PA, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998 May 6; 279(17):1343-4. http://www.ncbi.nlm.nih.gov/pubmed/9582033
  221. Deeks SG. Antiretroviral agents: the next generation. AIDS Clin Care. 1998 May; 10(5):33-6, 39-40. http://www.ncbi.nlm.nih.gov/pubmed/11365427
  222. Follansbee S, Deeks S, Bartnoff H. Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker. Newsline People AIDS Coalit N Y. 1998 Mar; 7-14. http://www.ncbi.nlm.nih.gov/pubmed/11367453
  223. Deeks S. Clinical implications of virological "failure": interview with Steven Deeks, M.D., San Francisco General Hospital. Interview by John S. James. AIDS Treat News. 1998 Feb 20; (No 289):1-6. http://www.ncbi.nlm.nih.gov/pubmed/11365047
  224. Deeks SG. Practical issues regarding the use of antiretroviral therapy for HIV infection. West J Med. 1998 Feb; 168(2):133-9. http://www.ncbi.nlm.nih.gov/pubmed/9499754
  225. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 1997 Dec; 176(6):1517-23. http://www.ncbi.nlm.nih.gov/pubmed/9395363
  226. Deeks S, Kertesz D, Ryan A, Johnson W, Ashton F. Surveillance of invasive meningococcal disease in Canada, 1995-1996. Can Commun Dis Rep. 1997 Aug 15; 23(16):121-5. http://www.ncbi.nlm.nih.gov/pubmed/9439039
  227. Deeks SG, Coleman RL, White R, Pachl C, Schambelan M, Chernoff DN, Feinberg MB. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J Infect Dis. 1997 Aug; 176(2):514-7. http://www.ncbi.nlm.nih.gov/pubmed/9237721
  228. Deeks SG, Abrams DI. Genotypic-resistance assays and antiretroviral therapy. Lancet. 1997 May 24; 349(9064):1489-90. http://www.ncbi.nlm.nih.gov/pubmed/9167453
  229. Deeks SG. New principles of HIV-related medical care. Focus. 1997 Apr; 12(5):5-7. http://www.ncbi.nlm.nih.gov/pubmed/11364329
  230. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997 Jan 8; 277(2):145-53. http://www.ncbi.nlm.nih.gov/pubmed/8990341
  231. Gordon M, Deeks S, De Marzo C, Goodgame J, Guralnik M, Lang W, Mimura T, Pearce D, Kaneko Y. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. J Med. 1997; 28(1-2):108-28. http://www.ncbi.nlm.nih.gov/pubmed/9249617
  232. Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev. 1997-1998; 145-85. http://www.ncbi.nlm.nih.gov/pubmed/9305448
  233. Eron JJ, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, Twaddell T. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet. 1996 Dec 7; 348(9041):1547-51. http://www.ncbi.nlm.nih.gov/pubmed/8950881
  234. Deeks S, Volberding P. An approach to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role. Hosp Pract (Minneap). 1995 Aug; 30 Suppl 1:23-31. http://www.ncbi.nlm.nih.gov/pubmed/7635914
  235. Deeks S, Richards J, Nandi S. Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. Exp Cell Res. 1988 Feb; 174(2):448-60. http://www.ncbi.nlm.nih.gov/pubmed/3276539